The FDA approved pembrolizumab for adults and children with relapsed or refractory classic Hodgkin lymphoma. This decision addresses the need for improved therapies in this patient population. John emphasized the poor prognosis for patients who do not respond to initial treatment or relapse after transplantation. Pembrolizumab as monotherapy offers a new option for these individuals, providing hope for improved outcomes.
Source link
Keytruda Granted Expanded Approval for Use in Classic Hodgkin Lymphoma
